AbbVie Exec Says Raising 2023 Skyrizi And Rinvoq Sales Forecast By $300M
Portfolio Pulse from Benzinga Newsdesk
AbbVie has raised its 2023 sales forecast for Skyrizi and Rinvoq by $300 million, according to a conference call cited by Reuters.
October 27, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's raised sales forecast for Skyrizi and Rinvoq could potentially boost its stock price.
AbbVie's decision to raise its sales forecast for Skyrizi and Rinvoq indicates a positive outlook for these products. This could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100